News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Cell Therapeutics, Inc. (CTIC) to Report Fourth Quarter and Full Year 2012 Financial Results After Market on February 28, 2013


2/26/2013 6:17:42 AM

SEATTLE, Feb. 26, 2013 /PRNewswire/ -- Cell Therapeutics, Inc.'s (CTI) (NASDAQ and MTA: CTIC) announced today that it will report its fourth quarter and full year 2012 financial results on Thursday, February 28, 2013, after the close of the U.S. financial markets. Following the announcement, members of the management team will host a webcast conference call to discuss the results and provide a general corporate update, at 4:30 p.m. ET (1:30 p.m. PT). Access to the event can be obtained as follows:

Thursday, February 28th
1:30 p.m. PT/4:30 p.m. ET/10:30 p.m. CET
1-877-941-6009 (domestic)
+1 480-629-9819 (international)

To access the live audio webcast or the subsequent archived recording, visit CTI's website, www.celltherapeutics.com. Webcast and telephone replays of the conference call will be available at approximately two hours after completion of the call. Callers can access the replay by dialing 1-800-406-7325 (domestic) or +1 303-590-3030 (international). The access code for the replay is 4603217#. The webcast will be recorded and available for replay on CTI's website until April 30, 2013.

About Cell Therapeutics, Inc.

Cell Therapeutics (NASDAQ and MTA: CTIC) is a biopharmaceutical company committed to the development and commercialization of an integrated portfolio of oncology products aimed at making cancer more treatable. CTI is headquartered in Seattle, WA. For additional information and to sign up for email alerts and get RSS feeds, please visit the company's website at www.CellTherapeutics.com.

Contacts:

Monique Greer
+1 206.272.4343
mgreer@ctiseattle.com

Ed Bell
+1 206.282.7100
invest@ctiseattle.com

SOURCE Cell Therapeutics, Inc.


Read at BioSpace.com

comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES